News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
122 Results
Type
Article (1)
Company Profile (1)
Press Release (120)
Section
Business (38)
Deals (4)
Drug Development (14)
FDA (2)
News (54)
Tag
2024 Genetown Standard (1)
Alliances (1)
Approvals (2)
Biotechnology (1)
Clinical research (6)
Compensation (1)
Data (3)
Duchenne muscular dystrophy (4)
Earnings (17)
Events (42)
Executive appointments (1)
FDA (3)
Featured Employer (1)
Healthcare (8)
IPO (4)
People (22)
Phase I (5)
Phase II (6)
Phase III (1)
Preclinical (8)
Startups (1)
United States (28)
Date
Last 7 days (3)
Last 30 days (5)
Last 365 days (32)
2025 (11)
2024 (31)
2023 (18)
2022 (19)
2021 (21)
2020 (15)
2019 (7)
122 Results for "Dyne_tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
March 11, 2025
·
1 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
March 21, 2025
·
2 min read
Press Releases
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
March 20, 2025
·
5 min read
Press Releases
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
March 17, 2025
·
11 min read
Press Releases
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025
·
1 min read
Press Releases
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
February 17, 2025
·
5 min read
Press Releases
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025
·
8 min read
Press Releases
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Press Releases
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
January 9, 2025
·
1 min read
Press Releases
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
January 21, 2025
·
6 min read
1 of 13
Next
